Emerson became CEO of this growing Minnetonka-based med-tech company (Nasdaq: AMMD) last January, taking over from long-time chief executive Douglas Kohrs, who remains as chairman. An accountant by training, Emerson plans to continue the company’s financial growth, “delivering top line at 18 to 22 percent, showing a nice, leveraged pickup at the bottom line in terms of profitability growth,” he says. “If you look at the last three or four years, we had a couple of acquisitions that were key to us from a technology-platform perspective, and we’ll continue to aggressively look at those types of acquisitions as we move forward.” Emerson expects the company to stay in the “pelvic health” market, which includes urological and gynecological ailments. The market is growing, he says, because people are living longer, are more willing to talk about their difficulties with their physicians, and “are more willing to do something about it.” Emerson also wants to increase the company’s global sales.